A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients (NCT03037489), a na phase 2 study. The primary outcome is Safety and Tolerability of MIV-711 in Osteoarthritis (OA) Patients.

2. Clinical Question

The central statistical question is descriptive: what adverse events were recorded during the defined observation periods? Without randomization or a concurrent control group, the data cannot isolate the effect of MIV-711 from the underlying condition, other care, or events that might have occurred without study treatment. Open-label status also means treatment assignment was known, which can affect event reporting and assessment.

The record reports serious and other adverse-event counts by group, along with zero deaths in each group. These figures provide a limited view of safety observations; they do not supply the full set of primary endpoint counts. The different observation timeframes also matter: a group followed over a longer period has more time in which an event can be observed. The record does not report enough information to make an adjusted or exposure-based comparison between the groups.

3. Trial Design

This was a Phase II extension study of MIV-711 in patients with knee joint osteoarthritis. The official title describes it as open-label and one-arm. The registry lists single-group modeling, no masking, and allocation as not applicable. It identifies Medivir as sponsor and lists an enrollment of 50. The study status is completed.

The registry gives a start date of 2016-09 and a primary completion date of 2017-11-28. The study description says MIV-711 was given for a total of 26 weeks. The primary outcome timeframe differs by group: Group A is listed as 0-56 weeks and Group B as 0-30 weeks. These observation windows should be kept distinct from the stated treatment duration. The registry record does not explain the reason for the different group timeframes or provide further details about the groups' composition.

Although adverse-event figures are displayed for Group A and Group B, those labels do not establish a randomized comparison. The record explicitly indicates that allocation was not randomized and that the groups are not a like-for-like control comparison. Consequently, a difference in event counts between groups cannot be interpreted as a treatment contrast. Their event counts also have different denominators, and the record does not provide an adjusted analysis accounting for follow-up duration or participant characteristics.

The extension design is relevant to interpretation: it addresses safety and tolerability during continued study treatment, rather than testing MIV-711 against placebo or another concurrent treatment. No masking is listed. The registry record does not report a statistical analysis plan, interim analyses, or a sample-size justification. The listed enrollment describes the study record; it does not establish a power target or show that the study was sized to detect a particular safety difference.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Safety and Tolerability of MIV-711 in Osteoarthritis (OA) Patients, measured over Group A: 0-56 weeks; Group B: 0-30 weeks.

The primary outcome is titled “Safety and Tolerability of MIV-711 in Osteoarthritis (OA) Patients” and uses participants as its unit. Its description lists counts of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), TEAEs related to treatment, mild, moderate, and severe TEAEs, and TEAEs leading to early discontinuation. These categories describe whether participants experienced specified safety events during follow-up; they are counts, not measures of symptom improvement or structural change in the joint.

Counting participants with an event is useful in safety monitoring because it gives a direct summary of how many people experienced an event in a defined category. Separate categories can distinguish seriousness, severity, assessed relationship to treatment, and consequences for continuing treatment. Those categories are not interchangeable: an event can be serious or non-serious, and seriousness is distinct from severity.

The record lists one primary outcome measure but does not report the numerical results for the listed TEAE categories. It does report separate serious and other adverse-event figures by group. Those figures should not be treated as a complete result for every primary endpoint category: category-specific counts for treatment-related, mild, moderate, severe, or discontinuation-leading TEAEs are not reported in the registry record. The endpoint's timeframe is 0-56 weeks for Group A and 0-30 weeks for Group B.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The endpoint is based on binary event status at the participant level: a participant is counted in a category if the relevant event criterion is met. The reported unit is participants, so the measure is not a count of all episodes when one person could have more than one event. A participant count can be useful for describing how many people were affected, but it does not convey the number, duration, or timing of episodes. Those details are not reported in the registry record.

What does a participant count tell the reader?

A count gives the number of participants meeting a specified event definition. To interpret a count, readers also need its denominator, the relevant observation window, and a clear definition of the event category. The posted serious and other adverse-event figures include groups and numbers at risk. The primary outcome's stated observation periods differ across groups. Since participants did not necessarily have identical observation windows, raw counts alone do not represent a common time-based event rate.

In general, a proportion is a count divided by the corresponding denominator. No additional percentages are calculated. A confidence interval around a proportion can help convey sampling uncertainty, with wider intervals generally indicating less precision. No confidence intervals are reported in the registry record. Small groups tend to yield less precise estimates, so a zero count does not demonstrate that the underlying event risk is zero. It means that no event was recorded in that group in the posted figures.

Why distinguish seriousness from severity?

Seriousness and severity describe different aspects of an adverse event. In general, seriousness is a regulatory classification based on outcomes or consequences, whereas severity describes the intensity of an event. A serious event is not necessarily the most severe event, and a severe event need not meet criteria for seriousness. The primary outcome description includes both SAE counts and mild, moderate, and severe TEAE counts, but numerical results for those severity categories are not reported in the registry record. The serious-event figures cannot fill that gap.

Why is a randomized comparison unavailable?

Random allocation can help make treatment groups comparable at baseline, supporting interpretation of between-group differences as treatment effects when the rest of the design and analysis are appropriate. This study is described as open-label, one-arm, and single-group, and allocation is listed as not applicable. Group A and Group B therefore should not be treated as randomized treatment and control arms. The registry record also cautions that they are not a like-for-like control comparison. Differences in observed counts could reflect group composition, follow-up time, or other factors, rather than treatment.

Masking is listed as none. In general, knowledge of treatment can influence reporting, clinical assessment, or decisions about whether an event is related to treatment. That possibility is relevant when interpreting subjective or investigator-assessed outcomes, but the registry record does not quantify any such influence in this study.

What do the planning assumptions mean?

The sample-size assumptions describe a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The illustration considers detecting a stated fraction of the observed effect. These assumptions are not a description of the trial's actual design: the study is recorded as single-group and does not have a randomized two-arm comparison. Such illustrations are planning tools, not observed power and not evidence that an effect exists. The registry record does not report a sample-size justification for the study itself.

For binary outcomes, planning calculations generally depend on the event frequency in each group and the difference the study aims to detect. If events are uncommon or groups are small, estimates may be unstable and the required sample size can be sensitive to assumptions. A planning calculation cannot repair a design without a valid comparator, nor can it convert descriptive event counts into a causal treatment estimate. No numerical planning results or inferential analyses are reported in the registry record.

What analysis details are missing?

The registry lists zero analyses. It does not report a statistical analysis plan, adjustment methods, confidence intervals, hypothesis tests, or an analysis population definition. The record also does not describe how missing outcome information was handled, how event relationships were adjudicated, or whether participants contributed different amounts of follow-up to the adverse-event summaries. These omissions limit reproducibility and make it difficult to assess the precision and completeness of the safety summaries.

Over-dispersion is a general issue for count outcomes when variability exceeds what a simple statistical model expects. It can matter when analyzing event counts or repeated events, but the posted participant-level summaries do not provide the information needed to assess over-dispersion. More broadly, no model-based analysis is reported, so no model assumptions should be attributed to the study beyond the stated assumptions for the planning illustration.

10. Multiplicity, Missing Data and Analysis Populations

The primary outcome description includes several safety categories: TEAEs, SAEs, treatment-related TEAEs, mild, moderate, and severe TEAEs, and events leading to early discontinuation. Assessing multiple categories can raise a multiplicity question: when several outcomes are examined, the chance of at least one apparently notable result can increase if each is tested separately. General approaches include prespecifying a primary comparison, adjusting inference, or treating results as exploratory. The registry record does not report a multiplicity strategy, and it reports zero analyses, so there are no posted tests to assess for such adjustment.

Numerical results are not reported in the registry record for most of the listed primary outcome categories. The serious and other adverse-event counts are available, but they do not provide the missing treatment-related, severity-specific, or discontinuation counts. Missing reporting should not be interpreted as zero events.

The registry record does not describe missing-data handling or define an analysis population. It is therefore unclear how participants with incomplete follow-up or missing event assessments were handled, or whether all enrolled participants contributed to each reported category. No assumptions about imputation, censoring, or exclusions can be made from the record. The different group observation timeframes further limit direct comparison, and the record does not report an analysis accounting for time at risk.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 4% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: angina pectoris (2.2%), atrial fibrillation (2.2%), cardiac failure (2.2%), ischaemic cardiomyopathy (2.2%), bronchiectasis (2.2%).

The serious adverse-event figures list 2 participants among 46 at risk in Group A and 0 among 4 at risk in Group B. The corresponding figures for other adverse events are 13 among 46 in Group A and 2 among 4 in Group B. Deaths are recorded as 0 for both groups. These are the counts in the registry record; they are not adjusted for different observation periods, and no confidence intervals are reported.

The groups have different listed primary outcome timeframes: 0-56 weeks for Group A and 0-30 weeks for Group B. Group B also has a smaller number at risk. Consequently, the raw counts should not be compared as if they arose from equally sized groups followed for the same amount of time. The study was not randomized, and the groups are not a like-for-like control comparison, so the difference in counts cannot be interpreted as a treatment effect.

The registry lists angina pectoris, atrial fibrillation, cardiac failure, ischaemic cardiomyopathy, bronchiectasis, and bronchitis chronic among the serious-event terms, each reported as 2.2%. Group attribution is not stated. Event terms and percentages alone do not establish causality, severity, timing, or how many participants experienced each term. Zero deaths in the posted figures does not mean that no serious adverse events occurred.

12. What the Result Does, and Does Not, Mean

The record shows that this completed open-label Phase II extension study collected safety and tolerability information for MIV-711 in people with knee osteoarthritis. Its posted group summaries include serious and other adverse-event counts and record zero deaths in each group. The primary outcome description covers a wider range of safety categories, but most category-specific counts are not reported in the registry record.

These data are descriptive, not comparative evidence of treatment effect. The study has no randomized comparator, and the two groups are explicitly not a like-for-like control comparison. The group observation periods differ, and the record does not provide an adjusted analysis or time-based event rates. It is not possible to attribute differences between groups to MIV-711 or to estimate what would have happened without treatment.

The record also does not provide confidence intervals or hypothesis tests. That absence means the precision of a comparative estimate cannot be evaluated; it does not mean there was no uncertainty or no difference. A zero count in a group is not proof that the risk is absent, particularly when the group is small. Likewise, an adverse event recorded during a study is not, by itself, proof that treatment caused it.

The findings should therefore be read as a limited account of reported safety events during the registry-defined observation windows. They do not establish the frequency of every primary endpoint category, demonstrate safety relative to another treatment, or settle the causal relationship between MIV-711 and individual events. The registry record does not report efficacy results, so no conclusion about clinical benefit can be drawn from these safety data.

13. Why This Trial Matters Statistically

Statistically, this study is a useful example of why design and reporting context matter as much as event counts. Adverse-event counts are easy to read at face value, but their interpretation depends on the denominator, observation period, event definition, and whether groups were constructed to support a comparison. Here the record lists two groups and different timeframes, but the study is described as one-arm and non-randomized, and the groups are not a like-for-like control comparison.

The example also highlights the distinction between a prespecified safety question and complete reporting of its components. The primary outcome description names treatment-emergent events, serious events, treatment-related events, severity levels, and discontinuation. Yet the registry record does not provide numerical results for most of these categories. A broad endpoint label does not substitute for detailed category-level results.

Small group counts demand particular caution. A count of zero or a small number of events can be compatible with substantial uncertainty about the underlying frequency, and raw counts are especially difficult to compare when groups have unequal follow-up. General statistical tools such as confidence intervals and exposure-adjusted rates can communicate uncertainty and account for time at risk, but those results are not reported.

Finally, planning assumptions should not be confused with evidence. The stated sample-size illustration uses a two-arm equal-allocation framework, whereas this registry record describes a single-group study. Recognizing that mismatch prevents a planning calculation from being mistaken for a trial-specific design justification, an observed power calculation, or proof of a treatment effect.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is the absence of a randomized concurrent comparator. The registry describes an open-label, one-arm extension with allocation listed as not applicable. Group A and Group B are not a like-for-like control comparison, so their event counts cannot establish a causal treatment contrast.

Follow-up differs by group: the primary outcome timeframe is 0-56 weeks for Group A and 0-30 weeks for Group B, while the group description states treatment for a total of 26 weeks. The record does not explain the differing observation windows or report event rates adjusted for time at risk. Raw counts may therefore reflect differing opportunity to observe events as well as differences in the groups.

Safety reporting is incomplete relative to the primary outcome description. Although the endpoint lists TEAEs, SAEs, treatment-related events, severity categories, and events leading to early discontinuation, the registry record does not provide numerical results for most of these categories. No analysis results, confidence intervals, or hypothesis tests are listed. Missing-data procedures, analysis populations, and methods for determining treatment relationship are also not reported in the registry record.

The record gives limited detail about the group composition and does not provide participant-level event timing or recurrent-event information. Group B has a small number at risk, which limits the precision of its descriptive counts. The serious-event terms are not attributed to a particular group in the record. These constraints limit evaluation of event frequency, comparative safety, and causality.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients — NCT03037489.
• Registry record last updated 2019-03-18; status last verified 2019-03.
• Results first posted 2019-03-18.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03037489 is a completed Phase II, open-label extension study of MIV-711 in patients with knee joint osteoarthritis, sponsored by Medivir. The registry lists an enrollment of 50, a start date of 2016-09, and a primary completion date of 2017-11-28. The study is described as one-arm and single-group, with no masking and no randomized allocation.

The primary outcome concerns counts of participants with treatment-emergent and serious adverse events, treatment-related events, events by severity, and events leading to early discontinuation. Its listed timeframe is 0-56 weeks for Group A and 0-30 weeks for Group B. The group description states MIV-711 treatment for a total of 26 weeks.

The registry reports serious and other adverse-event counts by group and records zero deaths in both. It lists one outcome measure and zero analyses. Most category-specific primary outcome counts, inferential results, missing-data methods, and a study-specific sample-size justification are not reported in the registry record. The group summaries are descriptive and do not constitute a randomized comparison.